본문 바로가기
KERD
논문KCI 등재

자궁경부암 유전자 치료를 위한 p53 종양 억제 유전자를포함한 아데노 연관 바이러스벡터 (AAVCMVp53)의 제조

Construction of Recombinant Adeno-Associated Virus Vector (AAVCMVp53)for Human Cervical Cancer Gene Therapy

이준모|진태영|이석우|김용완|김종국|안웅식|김용욱|배수미|남궁성은|김태형|서민제|전진근
대한산부인과학회 (Korean Soceity of Obstetrics and Gynecology)|2004.04|Obstetrics & Gynecology Science|제47권 제4호|pp. 695-701

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

자궁경부암Cervical cancerHelper plasmidAdeno-associated virus재조합 아데노 연관 바이러스Packaging 플라스미드Helper 플라스미드CotransfectionPackaging plasmid
주제분류산부인과학

초록

목적 : 재조합 아데노 연관 바이러스 rAAVCMVp53를 생산하기 위해서 3가지 플라스미드 pAAVp53, pAAVLacZ 벡터 플라스미드, packaging 플라스미드, helper 플라스미드를 사용하여 cotransfection 방법을 통해 아데노바이러스 오염이 없는 순수 rAAVCMVp53을 생산하고자 하였다. 연구 방법 : 벡터 플라스미드 (pAAVp53, pAAVLacZ), AAV를 암호한 부분에 2개의 p5 promoter를 가지는 플라스미드 pXX2 그리고 복제할 수 있는 능력을 지닌 플라스미드 pXX6 이용하여 293 세포주에 Ca++-phospate 침전법을 통해 cotransfection을 시행하고 CsCl 밀도구배 초원심분리를 이용하여 재조합 아데노 연관 바이러스를 생산하였다. 생성과 적정확인은 PCR과 dot-blot을 통해 분석하였다. 결과 : PCR 법에 의해 p53과 LacZ 유전자를 가지는 재조합 아데노 연관 바이러스의 생성을 확인하였으며 LacZ 유전자를 포함하는 재조합 아데노 연관 바이러스를 자궁경부암 세포주 HeLa, HT3, HeLaS3, CaSki 등에 감염시킨 후 X-gal 염색을 통해 이입을 확인하였다. 결론 : 벡터플라스미드, packaging 플라스미드, helper 플라스미드를 이용하여 cotransfection을 통한 아데노바이러스의 오염이 없는 재조합 아데노 연관 바이러스를 생산할 수 있게 되었다. 향후 cotransfection의 자세한 연구를 통해 높은 titer의 순수한 재조합 아데노 연관 바이러스를 다량으로 생산할 수 있을 것으로 사료된다.

Abstract

Objective : To eliminate the potential problem of adenovirus contamination during recombinant adeno- associated virus (rAAV) vector production, we investigated new rAAV production method by a triple transfection of vector plasmid, packaging plasmid, and adenovirus helper plasmid. Methods : This study was carried by triple transfection for the production of recombinant adeno- associated virus vector. This new production system was conducted with a plasmid construct which contained a mini-adenovirus genome capable of propagation of rAAV in the presence of adeno-assoceated viral rep and cap genes. To examine the helper functions of adenoviral plasmid on the production of rAAV vector, we carried out cotransfection with three plasmids, AAV vector, packaging construct, and adenovirus helper plasmids. The optimized plasmid quantity of transfection by calcium phosphate precipitation method was 25 µg of total plasmid DNA per 10 cm diameter plate of 293 cell. Results : We found that rAAV yields peaked at 48 hr after Ad infection. The titer of rAAV was measured by the dot blot analysis to measure the number of particles/mL based on the quantification of viral DNA. Conclusion : We constructed recombinant AAVp53 without adenovirus contamination. We thought that we construct high titer rAAVp53 particle through HPLC column in the near future

참고문헌 (35)

  1. "Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques", 8, pp.918~926 (2003)
  2. "Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing Arginine-Vasopressin in brattleboro rats", 8, pp.895~902 (2003)
  3. "Enhancement of gene transfer with recombinant adeno-associated virus rAAV vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides", 31, pp.1223~1229 (2003)
  4. "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony- stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", 90, pp.3539~4353 (1993)
  5. "Ex vivo gene therapy using bone marrow- derived cells:combined effects of intracerebral and intravenous transplantation in a mouse model of niemann-pick disease", 8, pp.876~885 (2003)
  6. "Ex vivo gene therapy in autologous critical-size craniofacial bone regeneration", 112, pp.1841~1850 (2003)
  7. "In vivo model of adeno-associated virus vector persistence and rescue", 70, pp.3235~3241 (1996)
  8. "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3", 91, pp.8802~8806 (1994)
  9. "Construction of adeno- associated virus packaging plasmids and cells that directly select for AAV helper functions", 114, pp.1~10 (2003)
  10. "Second-strand synthesis is a rate- limiting step for efficient transduction by recombinant adeno-associated virus vectors", 70, pp.3227~3234 (1996)
  11. "New developments in the generation of Ad-free,high-titer rAAV gene therapy vectors", 3, pp.1295~1297 (1997)
  12. "Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis", 70, pp.520~532 (1996)
  13. "Recombinant adeno-associated virus for muscle-directed gene therapy", 3, pp.306~312 (1997)
  14. "Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus", 94, pp.6916~6921 (1997)
  15. "Effect on malignant phenotypes of gastric cancer cell line after p53 gene transduction", 30, pp.508~522 (1998)
  16. "Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein", 93, pp.14082~14087 (1996)
  17. "Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers", 72, pp.4212~4223 (1998)
  18. "Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors", 94, pp.1426~1431 (1997)
  19. "A Study of retrovirus mediated p53 gene transduction into human gastric cancer cell lines", 29, pp.754~764 (1997)
  20. "The adeno-associated virus(AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection", 71, pp.1079~1088 (1997)
  21. "Enhancement of recombinant adeno- associated virus type 2-mediated transgene expression in a lung epithelial cell line by inhibition of the epidermal growth factor receptor", 77, pp.6394~6404 (2003)
  22. "Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors", 90, pp.229~238 (2003)
  23. "Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye", 43, pp.913~918 (2003)
  24. "Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver", 10, pp.1551~1558 (2003)
  25. "The adeno-associated virus type 2 p40 promoter requires a proximal Sp1 interaction and a p19 CArG-like element to facilitate Rep transactivation", 71, pp.4300~4309 (1997)
  26. "The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter", 71, pp.1747~1756 (1997)
  27. "Productive Replication of Adeno- associated Virus Can Occur in Human Papillomavirus Type 16(HPV-16) Episome-Containing Keratinocytes and Is Augmented by the HPV-16 E2 Protein", 74, pp.3494~3504 (2000)
  28. "Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells", 5, pp.3251~3260 (1985)
  29. "Analysis of recombinant Adeno- associated virus packaging and requirements for rep and cap gene products", 71, pp.1897~1905 (1997)
  30. "Receptor-mediated gene delivery and expression in vivo", 63, pp.14621~14624 (1988)
  31. "Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector", 70, pp.8098~8108 (1996)
  32. "Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus", 72, pp.2224~2232 (1998)
  33. "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", 91, pp.4407~4411 (1994)
  34. "Prolonged metabolic correction in adult ornithine transcarbamylase deficient mice with adenoviral vectors", 271, pp.3639~3646 (1996)
  35. "Systemetric gene expression after intravenous DNA delivery into adult mice", 261, pp.209~211 (1993)

관련 논문AI추천

인유두종 바이러스의 발암성 단백질의 발현을저해하는 Trans Attack 항암성 유전자 백신의 개발김대훈, 김도강, 김용완, 김재훈, 김종국, 김현정, 안웅식, 유영옥, 이성아, 이준모, 이진옥, 이희중, 남궁성은대한산부인과학회 · Obstetrics & Gynecology Science2004 · 제47권 제2호Cell-Specific Growth Inhibition of Human Cervical Cancer Cell by Recombinant Adenovirus p53 in vitro and in vivoChong Kook Kim, Jin Young Yoo, Joo Hee Yoon, Joon Mo Lee, Sang Lyun Nam, Su Mi Bae, Sung Eun Namkoong, Woong Shick Ahn, Yong-Wan Kim, Yong Wook Kim, Young-Seok Seo대한암학회 · Cancer Research and Treatment2003 · 제35권 제3호자궁경부암에서 p73 과발현과 Vascular Endothelial Growth Factor (VEGF) 및 Thrombospondin-1 (TSP-1) 생성과의 상관관계김승보, 서상기, 이선경, 지성길대한산부인과학회 · Obstetrics & Gynecology Science2006 · 제49권 제3호한국 여성의 자궁경부에서 아데노 연관 바이러스와고위험군 인유두종 바이러스 16과 18의 상관관계곽선영, 김동재, 김병훈, 김용욱, 김종국, 남계현, 배수미, 안웅식, 이성하, 이준모, 조영래, 최호선, 한병돈, 남궁성은대한산부인과학회 · Obstetrics & Gynecology Science2005 · 제48권 제2호Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter(hTERT)김정호, 신하연, 양재명, Chae-Ok Yun, Eunhee Kim, Han Saem Lee, Joo-Hang Kim, Joo-Hyuk Sohn대한암학회 · Cancer Research and Treatment2003 · 제35권 제3호침윤성 자궁경부암에서 Vascular Endothelial Growth Factor와 Angiopoietin-1 & -2 mRNA의 발현에 관한 연구김승철, 문혜성, 박한뫼, 안정자, 정혜원대한산부인과학회 · Obstetrics & Gynecology Science2004 · 제47권 제8호

이 간행물의 다른 논문 (10건)

정상 자궁 근육조직과 자궁근종에서의 이차원전기영동을 이용한 단백질 발현의 변화김민숙, 이준모, 김용욱, 안웅식, 배수미, 남궁성은, 김고운, 김종국, 노덕영, 이승구, 박은경pp. 618-626한국 폐경여성에서 부갑상선 호르몬 유전자 BstBI 다형성과골밀도 및 호르몬대체요법에 대한 골반응도 사이의 연관성문신용, 김석현, 최영민, 이진용, 김정구, 구승엽pp. 656-662인두유종 바이러스와 관련한 클라미디아 트라코마티스감염에 대한 임상적 고찰윤철구, 김재훈, 이희중, 이석우, 권동진, 박태철, 유영옥, 김대훈, 박동춘, 서경아pp. 670-677자간전증 환자에서 증가된 산화적 스트레스가 신생아의체중에 미치는 영향박혜숙, 박명걸, 김우경, 장남수, 박은애, 김영주, 하은희, 홍윤철, 박미혜pp. 702-707Ornithine transcarbamylase (OTC) 효소결핍증, 수포성표피박리증 및 lactic acidosis 가계에서 duplex nestedPCR 방법을 이용한 착상전 유전진단:OTC 효소결핍증 가계에서의 정상아 임신 및 출산김진영, 유한욱, 최혜원, 김수찬, 강인수, 전진현, 변혜경, 임천규, 궁미경, 이형송, 민동미pp. 708-718
원문 보기